Ratings HK inno.N Corporation

Equities

A195940

KR7195940002

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
37,950 ^KRW	-0.13%		-2.06%	-14.62%

2022	Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	CI
2022	Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The company benefits from high valuations in earnings multiples.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HK INNO.N CORPORATION	-14.62%	794M		-
MERCK KGAA	+6.97%	71.94B		A
SK BIOPHARMACEUTICALS CO., LTD.	-10.86%	5.13B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+46.43%	4.66B		-
YUHAN CORPORATION	+5.38%	3.97B		B-
BETTA PHARMACEUTICALS CO., LTD.	-16.20%	2.55B		C-
INDIVIOR PLC	+21.10%	2.41B		B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.20%	2.36B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.92%	2.21B	-	-
SUPERNUS PHARMACEUTICALS, INC.	+8.15%	1.71B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes